Biotech & Medtech
Biotech & Medtech news — Thursday 29 October 2026
22 stories from 3 sources, every one in English. Each links to its publisher.
-
What’s Driving the Rise of Consumer Diagnostics?
MedCity News
At MedCity INVEST Digital Health, experts from Jona, Labcorp and Evvy discussed the drivers of consumer diagnostics. The post What’s Driving the Rise of Consumer Diagnostics? appeared first on MedCity News .
-
Labor Department finalizes sweeping PBM disclosure rule
BioPharma Dive
Starting in 2027, the controversial drug middlemen will have to share a broad swath of fee and compensation data with self-funded employer clients. Employers cheered the rule, while PBMs slammed it as government overreach.
-
BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug
MedCity News
BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that…
-
STAT+: Federal judge rejects new Medicaid ‘frailty’ definition for work requirements
STAT News
A federal judge on Thursday rejected the federal government’s new definition of “medical frailty” and ruled that states did not have adequate time or resources to overhaul their eligibility systems, injecting new uncertainty into the…
-
STAT+: New federal rule will require prescription drug middlemen to share secret payments data
STAT News
The middlemen that oversee prescription drug spending for employers and workers will soon have to tell their clients all the different ways they get paid, a significant move that will unlock reams of highly protected data. The Trump…
-
STAT+: The EPIC investigation, and a Teladoc surprise
STAT News
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Big…
-
Genmab soars to record highs after cancer drug succeeds in key trial
BioPharma Dive
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.
-
HHS to allow compounders to make 6 unapproved peptides
BioPharma Dive
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested recommendation from outside advisers to the FDA in July.
-
STAT+: Kennedy’s closing arguments for the 2026 midterms: Fraud, vaccines, and MAHA
STAT News
On Wednesday night in Clive, Iowa, a parade of Make America Healthy Again activists and Republican candidates decried Big Agriculture, stressed the rise in chronic disease in America, and called for the Covid-19 vaccine to be removed from…
-
STAT+: El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptides
STAT News
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Care to test your knowledge of which…
-
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
STAT News
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I have a cold again. Cure it, science. HHS opens peptide floodgates, despite concerns from FDA scientists The Trump…
-
Martin Kulldorff critiques scientific gatekeepers at NIH lecture
STAT News
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Some really excellent stories today, including Anil Oza’s profile of Michigan Senate candidate Abdul El-Sayed and the next…
-
Beyond a Score: Putting The Patient Experience at the Heart of OCD Innovation
MedCity News
Scientific progress only really matters if it changes what life looks like for those living with OCD. That’s because for someone who has spent years losing hours to their obsessions and compulsions, meaningful progress should mean a…
-
STAT+: Vertex kidney disease drug scrutinized for infection risk
STAT News
This is the online version of Adam’s Biotech Scorecard, a weekly newsletter featuring exclusive, spicy analysis on the biotech industry. Sign up here to get it delivered to your inbox. Spain is amazing. I was in Madrid for five days…
-
STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
STAT News
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to … keep going. And why not? Just consider the alternatives. On that optimistic note…
-
3 Ways ProgenyHealth Can Transform Maternity and Infant Health, Claims Management
MedCity News
[Sponsored] Pregnancy and NICU admissions are among the most complex areas in healthcare. A new report from ProgenyHealth highlights how the company can work with Medicaid and commercial health plans to uncover insights and hidden risks…
-
Flagship blends three biotech startups to form Etcelera
BioPharma Dive
Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.
-
STAT+: New atlas of colorectal tumors sheds light on why cancers in young people are more dangerous
STAT News
For years, scientists have struggled to elucidate key biological differences between early onset colorectal cancer, typically in patients under the age of 50, and older patients. They’ve long believed that these cancers must be…
-
Opinion: Health care needs buyers willing to say no
STAT News
Right now, millions of workers are choosing their health plans for next year. The average family premium for employer coverage hit $28,303 in 2026, up 28% in the last five years. While employers appear to cover most of that premium…
-
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
STAT News
WASHINGTON — Ever since the Treasury Department proposed to limit U.S. investment in the Chinese biotech industry last week, players across the U.S. are arguing over the significance of the restrictions. The main debate to date had been…
-
Opinion: STAT+: Is AI more a partner, competitor, or crutch for biomedical scientists?
STAT News
Worried about artificial intelligence destroying all of humanity soon, or, alternatively, turning your toaster or other home appliances against you? For the moment, I’m most concerned about what it might be doing to science, specifically…
-
Politicians have failed to tackle health care affordability. It’s now voters’ rallying cry
STAT News
Voters across the country are furious over the high cost of health care, with resentment rippling across workers who get health coverage through their jobs. Polls from KFF , Pew Research Center , and CNN show Americans are fixated on…